Study Evaluating Enbrel in Patients With Rheumatoid Arthritis

Observational Study With Enbrel in Patients With Rheumatoid Arthritis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00245934

Enrollment

1500

Registered

2005-10-28

Start date

2003-06-30

Completion date

2005-07-31

Last updated

2007-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis

Brief summary

The purpose of this study is to investigate the incidence of adverse events for patients with rheumatoid arthritis treated with Enbrel under usual care settings. In addition, differences in injection site reactions based on whether health care professionals or patients administer Enbrel will be assessed and evaluated.

Interventions

DRUGEnbrel

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Proven diagnosis of rheumatoid arthritis

Exclusion criteria

* Contraindications according to Summary of Product Characteristic (SmPC)of Enbrel® the following points will prevent or restrict participation: * Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel® * Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localized infections * Patients with sepsis or risk of sepsis should not be treated

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026